Analyzing National Preparedness Plans for Pandemic Influenza
Author Information
Author(s): Lori Uscher-Pines, Saad B. Omer, Daniel J. Barnett, Thomas A. Burke, Ran D. Balicer
Primary Institution: Johns Hopkins Bloomberg School of Public Health
Hypothesis
How do national pandemic influenza plans prioritize vaccines and antiviral medications across different countries?
Conclusion
The study reveals significant variation in how countries prioritize vaccines and antiviral medications in their pandemic preparedness plans.
Supporting Evidence
- 40% of nations had identified cases of H5N1 in bird populations.
- 62% of plans were dated after June 2005.
- Only 40% of nations documented probable cases and/or deaths in their plans.
Takeaway
Countries have different plans for how to distribute vaccines and medicines during a pandemic, and some don't have clear strategies at all.
Methodology
The study reviewed 45 national pandemic influenza plans, analyzing their prioritization of vaccines and antiviral medications.
Potential Biases
Variation in plan formats and subjective categorization may limit the representation of planners' intents.
Limitations
The study relied on nonprobability sampling and may not fully capture the plans of developing nations.
Participant Demographics
The plans represented about 3.8 billion individuals, or roughly two-thirds of the world population.
Statistical Information
P-Value
p = 0.18 for vaccine prioritization, p = 0.10 for antiviral prioritization
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website